Optimizing the dose of imatinib for treatment of gastrointestinal stromal tumours: Lessons from the phase 3 trials

European Journal of Cancer

Volumn 44, Issue 4, 2008, Pages 501-509

  Patel, Shreyaskumar ^a   Zalcberg, John R ^b  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

Dose optimisation; Gastrointestinal stromal tumour; Genotype; Imatinib; KIT; Mutational analysis; Platelet derived growth factor receptor alpha

Indexed keywords

IMATINIB; PLATELET DERIVED GROWTH FACTOR ALPHA RECEPTOR; STEM CELL FACTOR RECEPTOR;

ADOLESCENT; ADULT; ARTICLE; CANCER GROWTH; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG DOSE COMPARISON; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG MEGADOSE; DRUG TOLERABILITY; EXON; GASTROINTESTINAL STROMAL TUMOR; GENE MUTATION; HUMAN; MULTICENTER STUDY; NEUTROPENIA; ONCOGENE C KIT; OVERALL SURVIVAL; PATIENT MONITORING; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; THROMBOCYTOPENIA;

ADOLESCENT; ADULT; AGED; ANTINEOPLASTIC AGENTS; CLINICAL TRIALS, PHASE III AS TOPIC; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GASTROINTESTINAL STROMAL TUMORS; HUMANS; MALE; MIDDLE AGED; MULTICENTER STUDIES AS TOPIC; MUTATION; PIPERAZINES; PROTO-ONCOGENE PROTEINS C-KIT; PYRIMIDINES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECEPTOR, PLATELET-DERIVED GROWTH FACTOR ALPHA; TREATMENT OUTCOME;

EID: 40249085621     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejca.2007.11.021     Document Type: Article

References (37)

1. Blackstein M.E., Blay J.Y., Corless C., et al. Gastrointestinal stromal tumours: consensus statement on diagnosis and treatment. Can J Gastroenterol 20 (2006) 157-163
2. D'Amato G., Steinert D.M., McAuliffe J.C., and Trent J.C. Update on the biology and therapy of gastrointestinal stromal tumors. Cancer Control 12 (2005) 44-56
3. Goettsch W.G., Bos S.D., Breekveldt-Postma N., Casparie M., Herings R.M., and Hogendoorn P.C. Incidence of gastrointestinal stromal tumours is underestimated: results of a nation-wide study. Eur J Cancer 41 (2005) 2868-2872
4. Joensuu H. Current perspectives on the epidemiology of gastrointestinal stromal tumours. Eur J Cancer 4 Suppl. 1 (2006) 4-9
5. Nilsson B., Bumming P., Meis-Kindblom J.M., Oden A., Dortok A., Gustavsson B., et al. Gastrointestinal stromal tumors: the incidence, prevalence, clinical course, and prognostication in the preimatinib mesylate era-a population-based study in western Sweden. Cancer 103 (2005) 821-829
6. Corless C.L., Fletcher J.A., and Heinrich M.C. Biology of gastrointestinal stromal tumors. J Clin Oncol 22 (2004) 3813-3825
7. Heinrich M.C., Corless C.L., Duensing A., et al. PDGFRA activating mutations in gastrointestinal stromal tumors. Science 299 (2003) 708-710
8. Hirota S., Isozaki K., Moriyama Y., et al. Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science 279 (1998) 577-580
9. Byrd DG, Demetri GD, Joensuu H, et al. Evaluation of imatinib mesylate (IM) in patients with large volume gastrointestinal stromal tumors (GISTs). In: American Society of Clinical Oncology Annual Meeting; 2007 June 1-5, 2007. Chicago, IL; 2007.
10. Buchdunger E., Cioffi C.L., Law N., et al. Abl protein-tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-kit and platelet-derived growth factor receptors. J Pharmacol Exp Ther 295 (2000) 139-145
11. Heinrich M.C., Griffith D.J., Druker B.J., Wait C.L., Ott K.A., and Zigler A.J. Inhibition of c-kit receptor tyrosine kinase activity by STI 571, a selective tyrosine kinase inhibitor. Blood 96 (2000) 925-932
12. Blay J.Y., Bonvalot S., Casali P., et al. Consensus meeting for the management of gastrointestinal stromal tumors. Report of the GIST consensus conference of 20-21 March 2004, under the auspices of European Society for Medical Oncology. Ann Oncol 16 (2005) 566-578
13. National Comprehensive Cancer Network. Clinical practice guidelines in oncology. Soft tissue sarcoma. Version 3.2006. [accessed January 27, 2007].
14. Demetri G.D., von Mehren M., Blanke C.D., et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med 347 (2002) 472-480
15. van Oosterom A.T., Judson I., Verweij J., et al. Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumours: a phase I study. Lancet 358 (2001) 1421-1423
16. van Oosterom A.T., Judson I.R., Verweij J., et al. Update of phase I study of imatinib (STI571) in advanced soft tissue sarcomas and gastrointestinal stromal tumors: a report of the EORTC Soft Tissue and Bone Sarcoma Group. Eur J Cancer 38 Suppl. 5 (2002) S83-S87
17. Verweij J., van Oosterom A., Blay J.Y., et al. Imatinib mesylate (STI-571 Glivec, Gleevec) is an active agent for gastrointestinal stromal tumours, but does not yield responses in other soft-tissue sarcomas that are unselected for a molecular target. Results from an EORTC Soft Tissue and Bone Sarcoma Group phase II study. Eur J Cancer 39 (2003) 2006-2011
18. Rankin C., Von Mehren M., Blanke C., et al. Dose effect of imatinib (IM) in patients (pts) with metastatic GIST-Phase III Sarcoma Group Study S0033 [abstract]. Proc Am Soc Clin Oncol 22 (2004) [Abstract 9005]
19. Verweij J., Casali P.G., Zalcberg J., et al. Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial. Lancet 364 (2004) 1127-1134
20. Glabbeke M.V., Verweij J., Casali P.G., et al. Initial and late resistance to imatinib in advanced gastrointestinal stromal tumors are predicted by different prognostic factors: a European Organisation for Research and Treatment of Cancer-Italian Sarcoma Group-Australasian Gastrointestinal Trials Group study. J Clin Oncol 24 (2005) 5795-5804
21. Van Glabbeke M., Verweij J., Casali P.G., et al. Predicting toxicities for patients with advanced gastrointestinal stromal tumours treated with imatinib: a study of the European Organisation for Research and Treatment of Cancer, the Italian Sarcoma Group, and the Australasian Gastro-intestinal Trials Group. Eur J Cancer 42 (2006) 2277-2285
22. Le Cesne A., Van Glabbeke M., Verweij J., et al. Is a stable disease according to RECIST criteria a real stable disease in GIST patients treated with imatinib mesylate (IM) included in the intergroup EORTC/ISG/AGITG trial? [abstract]. J Clin Oncol 24 (2006) 2 [June 20 Suppl., Abstract 9510]
23. Dileo P., Rankin C.J., Benjamin R.S., et al. Incidence and reasons for dose modification of standard-dose vs high-dose imatinib mesylate (IM) in the Phase III Intergroup Study S0033 of patients (pts) with unresectable or metastatic gastrointestinal stromal tumor (GIST) [abstract]. J Clin Oncol 23 16S (2005) 824s [Abstract 9032]
24. Heinrich MC, Shoemaker JS, Corless CL, et al. Correlation of target kinase genotype with clinical activity of imatinib mesylate (IM) in patients with metastatic GI stromal tumors (GISTs) expressing KIT (KIT+) [abstract]. In: 41st ASCO Annual Meeting. Orlando, FL. May 13-17, 2005. p. 3s.
25. Van Glabbeke M, Owzar K, Rankin C, Simes J, Crowley J, GIST Meta-analysis Group (MetaGIST). Comparison of two doses of imatinib for the treatment of gastrointestinal stromal tumors (GIST): a meta-analysis based on 1640 patients (pts) [abstract]. In: American Society of Clinical Oncology. Chicago, Illinois; June 1-5, 2007 [Abstract 10004].
26. Choi H., Charnsangavej C., Faria S.C., et al. Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: proposal of new computed tomography response criteria. J Clin Oncol 25 (2007) 1753-1759
27. Choi H., Charnsangavej C., de Castro Faria S., et al. CT evaluation of the response of gastrointestinal stromal tumors after imatinib mesylate treatment: a quantitative analysis correlated with FDG PET findings. AJR Am J Roentgenol 183 (2004) 1619-1628
28. Blanke C.D., Demetri G., von Mehren M., et al. Long-term follow-up of a phase II randomized trial in advanced gastrointestinal stromal tumor (GIST) patients (pts) treated with imatinib mesylate [abstract]. J Clin Oncol 24 18S (2006) 526s [Abstract 9528]
29. Casali P., Verweij J., Kotasek D., et al. Imatinib mesylate in advanced Gastrointestinal Stromal Tumors (GIST): survival analysis of the intergroup EORTC/ISG/AGITG randomized trial in 946 patients [abstract]. Eur J Cancer Suppl 2 (2005) 201 [Abstract 711]
30. Zalcberg J.R., Verweij J., Casali P.G., et al. Outcome of patients with advanced gastro-intestinal stromal tumours crossing over to a daily imatinib dose of 800 mg after progression on 400 mg. Eur J Cancer 41 (2005) 1751-1757
31. DeMatteo R.P., Lewis J.J., Leung D., Mudan S.S., Woodruff J.M., and Brennan M.F. Two hundred gastrointestinal stromal tumors: recurrence patterns and prognostic factors for survival. Ann Surg 231 (2000) 51-58
32. Debiec-Rychter M., Sciot R., Le Cesne A., et al. KIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumours. Eur J Cancer 42 (2006) 1093-1103
33. Blackstein M.E., Rankin C., Fletcher C., et al. Clinical benefit of imatinib in patients (pts) with metastatic gastrointestinal stromal tumors (GIST) negative for the expression of CD117 in the S0033 trial [abstract]. J Clin Oncol 23 16S (2005) 818s [Abstract 9010]
34. le Coutre P., Kreuzer K.A., Pursche S., et al. Pharmacokinetics and cellular uptake of imatinib and its main metabolite CGP74588. Cancer Chemother Pharmacol 53 (2004) 313-323
35. Horikoshi A., Takei K., and Sawada S. Relationship between daily dose of imatinib per square meter and its plasma concentration in patients with chronic-phase chronic myeloid leukemia (CML). Leuk Res 31 (2007) 574-575
36. Peng B., Hayes M., Resta D., et al. Pharmacokinetics and pharmacodynamics of imatinib in a phase I trial with chronic myeloid leukemia patients. J Clin Oncol 22 (2004) 935-942
37. Widmer N., Decosterd L.A., Csajka C., et al. Population pharmacokinetics of imatinib and the role of alpha-acid glycoprotein. Br J Clin Pharmacol 62 (2006) 97-112